NCCN VERSION 2 2015

175 / 188

Version 2.2015, 03/11/15 © National Comprehensive Cancer Network, Inc. 2015, All rights reserved. The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN®. MS-100
NCCN Guidelines Index
Breast Cancer Table of Contents
Discussion
NCCN Guidelines Version 2.2015
Breast Cancer
combined analysis of data from two mature phase III trials. Arimidex
Study Group. Cancer 1998;83:1142-1152. Available at:
452. Klijn JG, Blamey RW, Boccardo F, et al. Combined tamoxifen and
luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH
agonist alone in premenopausal advanced breast cancer: a meta-
analysis of four randomized trials. J Clin Oncol 2001;19:343-353.
Available at: .
453. Johnston S, Pippen J, Pivot X, et al. Lapatinib combined with
letrozole versus letrozole and placebo as first-line therapy for
postmenopausal hormone receptor-positive metastatic breast cancer. J
Clin Oncol 2009;27:5538-5546. Available at:
.
454. Kaufman B, Mackey JR, Clemens MR, et al. Trastuzumab plus
anastrozole versus anastrozole alone for the treatment of
postmenopausal women with human epidermal growth factor receptor
2-positive, hormone receptor-positive metastatic breast cancer: results
from the randomized phase III TAnDEM study. J Clin Oncol
2009;27:5529-5537. Available at:
.
455. Bachelot T, Bourgier c, Cropet C, et al. TAMRAD: A GINECO
randomized phase II trial of everolimus in combination with tamoxifen
versus tamoxifen alone in patients (pts) with hormone-receptor positive,
HER2 negative metastatic breast Cancer (MBC) with prior exposure to
aromatase inhibitors (AI) [abstract]. Cancer Res 2010;70(24
Supplement):Abstract: S1-6 Available at:
eetingAbstracts/S1-6.
456. Chow L, Sun Y, Jassem J, et al. Phase 3 study of temsirolimus
with letrozole or letrozole alone in postmenopausal women with locally
advanced or metastatic breast cancer. Breast Cancer Res Treat.
2006;100(Suppl 1):6091. Available at:
457. Yardley DA, Noguchi S, Pritchard KI, et al. Everolimus plus
exemestane in postmenopausal patients with HR(+) breast cancer:
BOLERO-2 final progression-free survival analysis. Adv Ther
2013;30:870-884. Available at:
.
458. Baselga J, Campone M, Piccart M, et al. Everolimus in
postmenopausal hormone-receptor-positive advanced breast cancer. N
Engl J Med 2012;366:520-529. Available at:
.
459. Pritchard KI, Burris HA, 3rd, Ito Y, et al. Safety and efficacy of
everolimus with exemestane vs. exemestane alone in elderly patients
with HER2-negative, hormone receptor-positive breast cancer in
BOLERO-2. Clin Breast Cancer 2013;13:421-432 e428. Available at:
.
460. Albain KS, Nag S, Calderillo-Ruiz G, et al. Global phase III study of
gemcitabine plus paclitaxel (GT) vs. paclitaxel (T) as frontline therapy
for metastatic breast cancer (MBC): First report of overall survival
[Abstract]. J Clin Oncol 2004;22:Abstract 510 Available at:
.
461. Carrick S, Parker S, Wilcken N, et al. Single agent versus
combination chemotherapy for metastatic breast cancer. Cochrane
Database Syst Rev 2005. Available at:
.
462. O'Shaughnessy J, Miles D, Vukelja S, et al. Superior survival with
capecitabine plus docetaxel combination therapy in anthracycline-
pretreated patients with advanced breast cancer: phase III trial results. J
Clin Oncol 2002;20:2812-2823. Available at:
.
463. Sledge GW, Neuberg D, Bernardo P, et al. Phase III trial of
doxorubicin, paclitaxel, and the combination of doxorubicin and
paclitaxel as front-line chemotherapy for metastatic breast cancer: an